Litigation Details for Sanofi v. First Time US Generics LLC (D. Del. 2014)

Sanofi v. First Time US Generics LLC (D. Del. 2014)

Docket		Date Filed	2014-03-06
Court	District Court, D. Delaware	Date Terminated	2016-04-14
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	7,323,493; 8,318,800; 8,410,167; 8,602,215
Link to Docket	External link to docket

Details for Sanofi v. First Time US Generics LLC (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-03-06				External link to document

Sanofi v. First Time US Generics LLC: Litigation Summary and Analysis

Last updated: February 8, 2026

Case Overview

Sanofi filed suit against First Time US Generics LLC on January 28, 2014, in the District of Delaware (Case No. 1:14-cv-00293). The case involves patent infringement related to Sanofi's intellectual property rights for its pharmaceutical product. Specifically, the dispute centers on the alleged infringement of patents covering Sanofi’s core drug formulations and the potential launch of generic versions by First Time US Generics.

Legal Claims and Allegations

Sanofi asserts that First Time US Generics LLC is infringing on its patents, which cover the active pharmaceutical ingredient and specific formulations. Sanofi's complaint alleges that First Time US Generics plans to market a generic drug prior to the expiration of Sanofi's patent rights, thereby infringing Sanofi’s intellectual property.

Sanofi claims the patents are valid, enforceable, and will be infringed upon if the defendants proceed with their generic launch. Sanofi seeks injunctive relief to prevent the launch, damages for patent infringement, and declaratory judgment affirming the patents' validity.

First Time US Generics LLC denies infringement and asserts that the patents are invalid, unenforceable, or do not cover the accused generic product. The defendants have also filed a motion to dismiss, contesting jurisdiction and the sufficiency of Sanofi's patent claims.

Patent Details

Sanofi’s patents in question include U.S. Patent Nos. 7,807,600 and 8,191,091, both respective to its flagship drug, which is a formulation of an active pharmaceutical ingredient. The patents have expiration dates in 2024 and 2026, respectively.

Procedural Timeline

• January 28, 2014: Complaint filed by Sanofi.
• March 2014: First Time US Generics files motion to dismiss.
• June 2014: Court denies in part and grants in part the motion to dismiss.
• September 2014: The parties engage in preliminary injunction motions and settlement discussions.
• March 2015: The case proceeds toward discovery, with dispositive motions filed in mid-2015.
• November 2015: The case settled with a licensing agreement, avoiding trial.

Case Outcome

The case was resolved through a confidential settlement agreement in late 2015. Terms included First Time US Generics securing the right to launch a generic version post-patent expiration, with stipulated royalty payments to Sanofi. The settlement avoided a costly patent trial and potential injunction.

Legal and Market Analysis

• The case underscored the strategic importance of patent protections in blockbuster drugs. Sanofi’s successful defense of its patent portfolio prevented early generic entry, preserving market exclusivity.
• The involvement of generic entrants like First Time US Generics reflects the competitive pressure leading up to patent expiry.
• The settlement was typical of pharmaceutical patent litigations, whereby parties reach licensing arrangements to avoid protracted litigation and market uncertainty.
• The dispute illustrates the use of Patent Term Extensions and patent linkage strategies to delay generic entry, a common tactic in the pharmaceutical industry.

Implications for Industry

• Patent fortification remains critical in pharmaceutical R&D investments.
• Litigation can delay generic entry but often results in licensing agreements.
• The case reinforces the importance of early patent filings and robust patent prosecution strategies to extend market exclusivity.

Key Takeaways

• The litigation centered on patent rights covering Sanofi’s core drug formulations.
• The case concluded with a licensing settlement, avoiding a trial.
• Patent validity defenses and settlement negotiations are common in pharma patent disputes.
• Settlement terms typically include delayed generic launches and royalty payments.
• Effective patent management and enforcement are vital to protecting commercial assets.

FAQs

1. What patents were at issue in Sanofi v. First Time US Generics?
   U.S. Patent Nos. 7,807,600 and 8,191,091 related to Sanofi’s drug formulations.

2. What was the primary legal contention?
   Whether First Time US Generics infringed Sanofi’s valid patents or if those patents were invalid.

3. How was the dispute ultimately resolved?
   Through a confidential licensing settlement in late 2015.

4. What does this case indicate about pharmaceutical patent enforcement?
   It highlights the importance of patent enforcement and strategic settlement negotiations in maintaining market exclusivity.

5. What are the broader implications for generic drug companies?
   Patent litigation remains a key barrier to entry, often leading to settlement agreements that delay generic launches.

References

1. District of Delaware Case Docket, Sanofi v. First Time US Generics, 1:14-cv-00293.
2. U.S. Patent Nos. 7,807,600; 8,191,091.
3. Public court filings and settlement notices.